TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02850367

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate
Description: Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate and L-Arginine
Description: Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate and L-Citrulline
Description: Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate and L-Citrulline
Description: Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of post-ischemic vascular reactivity
Description: After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of post-ischemic vascular reactivity
Description: After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular evaluations
Description: After the intake of the supplement. Measure the stretching force in the ankle (N)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular evaluations
Description: After the intake of the supplement. Measure the stretching force in the ankle (N)
Study: NCT00419133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Killed bivalent whole cell oral cholera vaccine
Description: Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Heat Killed E. coli Placebo
Description: Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
Study: NCT03339570

Intervention type: PROCEDURE
Intervention: Orthopedic treatment for a proximal humeral fracture
Description: Orthopedic treatment consisting in inmobilization of the arm in a sling for the first three weeks, followed by physical therapy.
Study: NCT02788903

Intervention type: OTHER
Intervention: Weight Counseling
Description: This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.

Intervention type: OTHER
Intervention: Weight Counseling
Description: This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
Study: NCT03713736

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pregnancy test
Description: Urinary pregnancy test
Study: NCT03609684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gymnastic and Core Stabilization
Description: People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Only Gymnastic Training
Description: People can do gymnastics twice a week but can't do core stabilization exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary Group
Description: People who are not interested in any sports and don't do any exercises
Study: NCT00138671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Study: NCT03713736

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sexual activity questionnary
Description: Sexual activity questionnary
Study: NCT04018755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anakinra
Description: anakinra single-use prefilled glass syringes
Study: NCT01025726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Police Patrolled Walking plus Social Marketing
Description: Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Police Patrolled Walking Program Only
Description: Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Description: Host community events for chronic disease education
Study: NCT02624076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
Study: NCT00138671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin
Description: Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
Study: NCT02624076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expectant management
Description: one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: expectant management
Description: one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
Study: NCT02600234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inter-Atrial Shunt Device
Description: An implantable device placed in the interatrial septum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intracardiac Echo
Description: Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
Study: NCT02157025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care procedures during Humphrey perimetry for children
Study: NCT02614300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation and Chest Physiotherapy
Description: The patient will come 3 times per week during 12 weeks Each session 1h15min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: The patient will come 3 times per week during 12 weeks Each session 45min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest Physiotherapy
Description: The patient will come 3 times per week during 12 weeks Each session 30min
Study: NCT03938090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimised MultiSite Pacing
Description: The intervention includes using optimal programming settings with MultiSite pacing configurations via the patient's CRT device. The device in use is the same for each arm, the only changes are the programming settings.
Study: NCT00099736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF 2 g + full-dose Neoral (FDN) + corticosteroids
Description: mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
Study: NCT02921477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Study: NCT01673958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Comparison between stair descending and stair ascending training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Comparison between stair descending and stair ascending training
Study: NCT00789425

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Extract of Olive Polyphenols
Description: Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
Study: NCT04253574

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging with 18F-FDG PET/CT and/or Ultrasound
Description: All patients were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)) in the search of primary tumors or metastases of their malignant melanomas.
Study: NCT02777385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
Study: NCT03869723

Intervention type: PROCEDURE
Intervention: Virtual planning using customized surgical devices
Description: Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken

Intervention type: PROCEDURE
Intervention: Conventional surgery
Description: Classical surgery for mandibular reconstruction with fibula free flap
Study: NCT02902705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)
Description: The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
Study: NCT03938090

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard biventricular pacing
Description: Conventional programming settings using biventricular pacing will be used
Study: NCT02902705

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)
Description: The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
Study: NCT02943226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Becton Dickinson Nexiva Diffusics System
Description: Becton Dickinson Nexiva Diffusics System will be used to inject IV contrast and will be compared to a single hole catheter to see if it improves image quality in the main vessels in the abdomen and pelvis because of its novel design.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard intravenous catheter
Description: Standard catheter with one hole at the tip will be compared to a novel 3 hole catheter to see which catheter provides the best image quality.
Study: NCT03126591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Administered IV
Study: NCT02741063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: screen low autistic subjects
Description: screen subjects with low ASQ score

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: screen low autistic subjects
Description: screen subjects with low ASQ score

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: screen high autistic subjects
Description: screen subjects with high ASQ score

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: screen high autistic subjects
Description: screen subjects with high ASQ score

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: intranasal administration of oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: intranasal administration of oxytocin (24 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intranasal administration of placebo (24 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intranasal administration of placebo (24 IU)
Study: NCT04734028

Intervention type: DRUG
Intervention: Clopidogrel Tablets
Description: DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily
Study: NCT01716377

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venlafaxine
Description: Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
Study: NCT03989258

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mammography outside official screening
Description: Radiologic study

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mammography outside official screening
Description: Radiologic study
Study: NCT01586546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face MBM Skills Group
Description: Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control I
Description: No intervention offered during study period. Intervention is offered after completion of study.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control II
Description: No intervention offered during study period. Intervention is offered after completion of study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online MBM Skills Group
Description: Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
Study: NCT04177823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be available as lyophilized powder 100 mg/vial in single-use vial for reconstitution. It will be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on Day 1 of each cycle over 30 minutes.
Study: NCT01387477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactate
Description: Infusion of 66 mmol of lactate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Infusion of 33 mmol of glucose
Study: NCT01393821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menadione topical lotion
Description: Given topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Given menadione topical lotion
Study: NCT02286349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (Neurosoft®)
Description: Repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation (Neurosoft®)
Description: Repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (Soterix, USA)
Description: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (Soterix, USA)
Description: Transcranial direct current stimulation
Study: NCT01106612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography
Description: EKG-gated, computed tomography angiography of the coronary arteries during heart rate control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial perfusion imaging
Description: Stress radionuclide myocardial perfusion imaging
Study: NCT04323969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific Modification Target
Description: Participants will be instructed to increase their baseline foot progression angle by 15 degrees. Visual feedback during practice will be delivered using a mirror and guideline (tape placed on mirror). Verbal feedback will be incorporated to encourage participants to perform the modified foot progression angle as accurately as possible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed Modification
Description: Participants will be instructed to modify their foot progression angle as much as is comfortable. A mirror will be used during practice for visual feedback, but no specific target or guide will be provided.
Study: NCT02368496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Study: NCT02116036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Study: NCT00761995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt
Description: topical eye drop dosed 1 drop 3 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt
Description: topical eye drop dosed 1 drop 2 times daily
Study: NCT03779295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse laser dye therapy (Device name: Candela Family of Pulsed Dye Laser Systems. 501k Number: K050673.)
Description: The face will be split and randomized, one half will receive pulsed laser dye therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: The entire face (both halves) will receive clindamycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: The entire face (both halves) will receive clindamycin.
Study: NCT00854750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR
Description: SQ weekly injections